Background: Diabetic kidney disease (DKD) is a chronic progressive disorder which is a leading cause of chronic kidney disease (CKD). As an important pathogenesis of DKD, the overproduction of reactiv
Breast cancer is the most common malignancy, with approximately ∼20% of cases involving HER2 overexpression. Trastuzumab deruxtecan (T-DXd), an HER2-targeted antibody–drug conjugate, is approved for H
BackgroundNilotinib, which inhibits cellular Abelson tyrosine kinase, may be an effective treatment for patients with Parkinson's disease (PD). The purpose of this study is to evaluate the outcomes of
Supplemental Materials for "Targeting the Opioid Pathway for the Treatment of Chronic Kidney Disease Associated Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"
